Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities.

Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Lax S, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1089-1109. doi: 10.1055/a-0715-2964. Epub 2018 Nov 26.

2.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Sigurd L, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):949-971. doi: 10.1055/a-0713-1218. Epub 2018 Oct 19.

3.

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.

Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W, Friedl TWP; SUCCESS Study Group.

Oncol Res Treat. 2018;41(3):93-98. doi: 10.1159/000485566. Epub 2018 Feb 27.

4.

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.

Oncotarget. 2017 May 9;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

5.

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.

Hein A, Rack B, Li L, Ekici AB, Reis A, Lux MP, Cunningham JM, Rübner M, Fridley BL, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L, Fasching PA, Häberle L.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):651-659. doi: 10.1055/s-0042-113189. Epub 2017 Jun 28.

6.

Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.

Koensgen D, Sehouli J, Belau A, Weiss M, Stope MB, Grokopf V, Eichbaum M, Ledwon P, Lichtenegger W, Zygmunt M, Köhler G, Mustea A.

Int J Gynecol Cancer. 2017 Mar;27(3):500-506. doi: 10.1097/IGC.0000000000000894.

PMID:
28187089
7.

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.

Rack B, Jückstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, Lato K, Zwingers T, Lorenz R, Tesch H, Schneeweiss A, Fasching P, Mahner S, Beckmann MW, Lichtenegger W, Janni W; SUCCESS Study Group.

Tumour Biol. 2016 Oct;37(10):13769-13775. Epub 2016 Aug 1.

PMID:
27481512
8.

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.

Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W; SUCCESS Study Group.

BMC Cancer. 2016 Jul 7;16:401. doi: 10.1186/s12885-016-2454-3.

9.

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.

Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W; SUCCESS Study Group.

J Natl Cancer Inst. 2014 May 15;106(5). pii: dju066. doi: 10.1093/jnci/dju066. Erratum in: J Natl Cancer Inst. 2014 Sep;106(9):doi/10.1093/jnci/dju273.

10.

Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.

Braicu EI, Gasimli K, Richter R, Nassir M, Kümmel S, Blohmer JU, Yalcinkaya I, Chekerov R, Ignat I, Ionescu A, Mentze M, Fotopoulou C, Pop C, Lichtenegger W, Sehouli J; Tumor Bank Ovarian Cancer (TOC); German North Eastern Society for Gynecological Oncology (NOGGO).

Anticancer Res. 2014 Jan;34(1):385-91.

PMID:
24403492
11.

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).

Mustea A, Koensgen D, Belau A, Sehouli J, Lichtenegger W, Schneidewind L, Sommer H, Markmann S, Scharf JP, Ehmke M, Ledwon P, Braicu I, Zygmunt M, Koehler G.

Cancer Chemother Pharmacol. 2013 Nov;72(5):975-83. doi: 10.1007/s00280-013-2276-9. Epub 2013 Sep 1.

PMID:
23995698
12.

Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.

Braicu EI, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kümmel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J.

Cytokine. 2013 Mar;61(3):755-8. doi: 10.1016/j.cyto.2013.01.013. Epub 2013 Feb 14.

PMID:
23415672
13.

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.

Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S.

Ann Oncol. 2012 Sep;23(9):2259-2264. doi: 10.1093/annonc/mdr628. Epub 2019 Dec 4.

PMID:
32018694
14.

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.

Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S.

Ann Oncol. 2012 Sep;23(9):2259-64. doi: 10.1093/annonc/mdr628. Epub 2012 Feb 21.

15.

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

J Clin Oncol. 2011 Oct 1;29(28):3791-7. doi: 10.1200/JCO.2010.30.4899. Epub 2011 Aug 22.

PMID:
21860000
16.

Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.

Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Özcelik G, Lichtenegger W, Sehouli J.

Anticancer Res. 2011 Aug;31(8):2679-82.

PMID:
21778323
17.

Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer.

Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stöblen F, Lichtenegger W, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2651-5.

PMID:
21778318
18.

The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer.

Landt S, Heidecke H, Reuter C, Korlach S, Blohmer JU, Lichtenegger W, Heusner T, Stöblen F, Thill M, Barinoff J, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2645-9.

PMID:
21778317
19.

Prognostic significance of angiogenic factors in uterine cervical cancer.

Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2589-95.

PMID:
21778309
20.

Predictive factors in relapsed ovarian cancer for complete tumor resection.

Gil-Ibáñez B, Oskay-Özcelik G, Richter R, Fotopoulou C, Braicu EI, Neuhaus P, Lichtenegger W, Sehouli J; Tumor Bank Ovarian Cancer Network (TOC); European Competence Centre for Ovarian Cancer (EKZE Berlin).

Anticancer Res. 2011 Aug;31(8):2583-7.

PMID:
21778308
21.

Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.

Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C.

Eur J Cancer. 2012 Mar;48(5):687-94. doi: 10.1016/j.ejca.2011.06.034. Epub 2011 Jul 13.

PMID:
21757333
22.

Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking.

Fotopoulou C, Richter R, Braicu EI, Kuhberg M, Feldheiser A, Schefold JC, Lichtenegger W, Sehouli J.

Ann Surg Oncol. 2011 Sep;18(9):2629-37. doi: 10.1245/s10434-011-1637-z. Epub 2011 Mar 11.

PMID:
21394662
23.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G.

J Clin Oncol. 2011 Jan 10;29(2):242-8. doi: 10.1200/JCO.2009.27.8911. Epub 2010 Nov 29.

PMID:
21115872
24.

Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.

Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C.

Int J Gynecol Cancer. 2010 Nov;20(8):1331-40. doi: 10.1111/IGC.0b013e3181f15714.

PMID:
21051973
25.

What are the individual perceptions of patients with borderline tumours of the ovary in regard to pathogenesis and prognosis? A structured survey on 60 women.

Fotopoulou C, Bugariu M, Braicu EI, Lichtenegger W, Sehouli J.

J Psychosom Obstet Gynaecol. 2010 Dec;31(4):265-72. doi: 10.3109/0167482X.2010.528091. Epub 2010 Nov 2.

PMID:
21039327
26.

Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.

Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J.

Eur J Surg Oncol. 2010 Dec;36(12):1202-10. doi: 10.1016/j.ejso.2010.09.008. Epub 2010 Sep 22.

PMID:
20864305
27.

Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients.

Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C.

J Surg Oncol. 2010 Nov 1;102(6):656-62. doi: 10.1002/jso.21652.

PMID:
20734422
28.

Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.

Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J.

Ann Surg Oncol. 2011 Jan;18(1):49-57. doi: 10.1245/s10434-010-1245-3. Epub 2010 Aug 10.

PMID:
20697821
29.

Expression and localization of e-cadherin in epithelial ovarian cancer.

Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J.

Anticancer Res. 2010 Jul;30(7):2525-30.

PMID:
20682978
30.

Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome.

Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, Sehouli J.

Gynecol Oncol. 2010 Nov;119(2):285-90. doi: 10.1016/j.ygyno.2010.06.031. Epub 2010 Jul 15.

PMID:
20637497
31.

Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment.

Rack B, Schindlbeck C, Jückstock J, Genss EM, Hepp P, Lorenz R, Tesch H, Schneeweiss A, Beckmann MW, Lichtenegger W, Sommer H, Friese K, Janni W; SUCCESS Study Group.

Anticancer Res. 2010 May;30(5):1837-41.

PMID:
20592389
32.

Clinical management of borderline tumours of the ovary - experience from the "Berlin online tumour conference for gynaecological malignancies".

Sehouli J, Oskay-Oezcelik G, Pietzner K, Chen F, Coumbos A, Darb-Esfahani S, Schuback B, Heinrich G, Kronenberger C, Lorsbach M, Lichtenegger W, Chekerov R.

Anticancer Res. 2010 May;30(5):1701-6.

PMID:
20592364
33.

External iliac artery ligation due to late postoperative rupture after radical lymphadenectomy for advanced ovarian cancer--two case reports.

Fotopoulou C, Neumann U, Kraetschell R, Lichtenegger W, Sehouli J.

Eur J Gynaecol Oncol. 2010;31(2):198-200.

PMID:
20527240
34.

Reconstructive surgical management of cryptomenorrhea because of complex uterovaginal malformations with duplicate uterus and complete vaginal agenesis.

Fotopoulou C, Gehrmann N, Sehouli J, Lichtenegger W.

Fertil Steril. 2010 Nov;94(6):2329.e13-6. doi: 10.1016/j.fertnstert.2010.03.058. Epub 2010 May 5.

PMID:
20447626
35.

Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.

Fotopoulou C, Neumann U, Kraetschell R, Schefold JC, Weidemann H, Lichtenegger W, Sehouli J.

J Surg Oncol. 2010 May 1;101(6):507-12. doi: 10.1002/jso.21518.

PMID:
20401918
36.

Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.

Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S, Ulm K, Schmidt P, Blohmer JU, Lichtenegger W, Sehouli J, Kuemmel S.

Anticancer Res. 2010 Feb;30(2):375-81.

PMID:
20332442
37.

Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.

Fotopoulou C, Cho CH, Kraetschell R, Gellermann J, Wust P, Lichtenegger W, Sehouli J.

Int J Hyperthermia. 2010;26(2):118-26. doi: 10.3109/02656730903369200.

PMID:
20146566
38.

Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival.

Fotopoulou C, Savvatis K, Steinhagen-Thiessen E, Bahra M, Lichtenegger W, Sehouli J.

Int J Gynecol Cancer. 2010 Jan;20(1):34-40. doi: 10.1111/IGC.0b013e3181c10c04.

PMID:
20130501
39.

Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status.

Fotopoulou C, Savvatis K, Kraetschell R, Schefold JC, Lichtenegger W, Sehouli J.

Eur J Obstet Gynecol Reprod Biol. 2010 Apr;149(2):199-203. doi: 10.1016/j.ejogrb.2009.12.021. Epub 2010 Jan 22.

PMID:
20096987
40.

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.

Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G, Wischnewsky MB, Lichtenegger W, Kuemmel S.

Ann Oncol. 2010 Jul;21(7):1430-5. doi: 10.1093/annonc/mdp585. Epub 2010 Jan 20.

41.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.

Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G.

Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7.

PMID:
20054549
42.

The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer.

Rack B, Andergassen U, Neugebauer J, Salmen J, Hepp P, Sommer H, Lichtenegger W, Friese K, Beckmann MW, Hauner D, Hauner H, Janni W.

Breast Care (Basel). 2010;5(6):395-400. Epub 2010 Dec 8.

43.

Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.

Oskay-Ozcelik G, Chekerov R, Sommer H, Keil E, Einenkel J, Pfisterer J, Lorenz-Schlüter C, Lichtenegger W, Camara O, Sehouli J.

Gynecol Oncol. 2010 Mar;116(3):317-22. doi: 10.1016/j.ygyno.2009.09.031. Epub 2009 Dec 2.

PMID:
19959213
44.

Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary.

Fotopoulou C, Schumacher G, Schefold JC, Denkert C, Lichtenegger W, Sehouli J.

Int J Gynecol Cancer. 2009 Dec;19(9):1550-5. doi: 10.1111/IGC.0b013e3181a84699.

PMID:
19955936
45.

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study.

Koensgen D, Oskay-Oezcelik G, Katsares I, Walle U, Klapp C, Mustea A, Stengel D, Porzsolt F, Lichtenegger W, Sehouli J; Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group "Quality of life".

Support Care Cancer. 2010 Aug;18(8):931-42. doi: 10.1007/s00520-009-0733-0. Epub 2009 Sep 17.

PMID:
19760286
46.

Surgical outcome and survival analysis of young patients with primary epithelial ovarian cancer.

Fotopoulou C, Savvatis K, Schumacher G, Lichtenegger W, Sehouli J.

Anticancer Res. 2009 Jul;29(7):2809-15.

47.

Brain metastases from epithelial ovarian cancer: overview and optimal management.

Pietzner K, Oskay-Oezcelik G, El Khalfaoui K, Boehmer D, Lichtenegger W, Sehouli J.

Anticancer Res. 2009 Jul;29(7):2793-8. Review.

48.

Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer.

Chen FC, Oskay-Ozcelik G, Bühling KJ, Köpstein U, Mentze M, Lichtenegger W, Sehouli J.

Anticancer Res. 2009 May;29(5):1575-8.

49.

Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany.

Coumbos A, Sehouli J, Chekerov R, Schaedel D, Oskay-Oezcelik G, Lichtenegger W, Kuehn W; North-Eastern German Society of Gynecological Oncology (NOGGO).

Br J Cancer. 2009 Jun 2;100(11):1731-8. doi: 10.1038/sj.bjc.6605065. Epub 2009 May 12.

50.

Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).

Fotopoulou C, Karavas A, Trappe R, Chekerov R, Lichtenegger W, Sehouli J.

Thromb Res. 2009 Nov;124(5):531-5. doi: 10.1016/j.thromres.2009.03.013. Epub 2009 May 8.

PMID:
19427025

Supplemental Content

Loading ...
Support Center